000			02879cam a2200337 a 4500
003			EG-GiCUC
005			20250223031524.0
008			160620s2016 ua f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.08.06.M.Sc.2016.Ge.D
100	0		_aGehad Mohsen Yassin
245	1	0	_aDesign and testing of a novel peptide vaccine against the mucosal pathogen moraxella catarrhalis with emphasis on protecting chronic obstructive pulmonary disease patients from exacerbations / _cGehad Mohsen Yassin ; Supervised Magdy Ali Amin , Ahmed Sherif Attia
246	1	5	_aتصميم و اختبار لقاح بيبتيدى جديد ضد الممراض المخاطى المسمى بالموركسيلة النزلية لحماية مرضى الداء الرئوى المسد المزمن من نشاط المرض
260			_aCairo : _bGehad Mohsen Yassin , _c2016
300			_a132 Leaves ; _c25cm
502			_aThesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Microbiology and Immunology
520			_aMoraxella catarrhalis is an established pathogen that is causing substantial infections to both children and adults. However, so far there is not effective vaccine that could halt the spread of these infections. Immunoinformatics tools were used to predict M. catarrhalis epitopes that would be capable of offering immunoprotection among major proportions of human populations worldwide. Mice were immunized with best three peptides then challenged with M. catarrhalis in the pulmonary clearance model. Finally, antibodies against these epitopes were detected in humans. Immunoinformatics analyses identified 44 epitopes which are predicted to be good MHC II binders and at the same time show high population coverages worldwide. Upon intraprotenial mice immunization with the best three peptides, peptide 2A3 derived from the lactoferrin binding protein A showed superior activity in immunogenicity and in clearing M. catarrhalis from mice lungs. Higher clearance was obtained upon combining intraprotenial with intranasal immunization. Upon examining the sera from otitis media children infected with M. catarrhalis, antibodies levels against peptide 2A3 were significantly higher than those detected in non otitis media ones. Peptide 2A3 is the first promising peptide based vaccine against M. catarrhalis. Immunoinformatics predicts it should have a global protection around the world.
530			_aIssued also as CD
653		4	_aExacerbations
653		4	_aMucosal pathogen moraxella
653		4	_aNovel peptide vaccine against
700	0		_aAhmed Sherif Attia , _eSupervisor
700	0		_aMagdy Ali Amin , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aNazla _eRevisor
905			_aSamia _eCataloger
942			_2ddc _cTH
999			_c56982 _d56982